

## **ImmunoCellular Appoints Two New Members to Scientific Advisory Board**

**LOS ANGELES, CA – July 8, 2010** – ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) , announced today that it has appointed Zvi Ram, M.D. and John Boockvar, M.D. to its Scientific Advisory Board. Dr. Ram is the Chairman of the Department of Neurosurgery at Tel Aviv Medical Center in Israel. Dr. John Boockvar is Co-Director of the Brain and Spinal Tumor Program at Weill Cornell Medical College. Dr. Ram and Dr. Boockvar join an accomplished Scientific Advisory Board that is expected to support the Company's efforts later this year to commence a Phase II trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM). In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who received the vaccine in addition to the standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent.

Prior to joining the Tel Aviv Medical Center, Dr. Ram was with the Surgical Neurology Branch of the National Institutes of Health, where he led many clinical research projects, most notably leading the first gene therapy trial for patients with brain tumors. Dr. Ram holds a number of esteemed positions with other organizations as well, including as the Chairman of the European Association of Neurosurgical Society's Neurooncology Committee, a member of the Executive Steering Committees, lead PI for several pharmaceuticals companies, scientific advisor to several biotechnology groups, and a member of editorial boards for a number of leading scientific journals. His areas of expertise include surgery for complex brain tumors, including performance of Awake Craniotomies with intra-operative cortical mapping and white matter tracking when tumors are within or near functional brain regions, resection of pituitary tumors and complex benign tumors of the brain.

Dr. Boockvar is a board-certified neurosurgeon who specializes in treating brain and spinal tumors. At Weill Cornell Medical College, Dr. Boockvar heads the Brain Tumor and Stem Cell Research Laboratory and directs the institution's Brain Tumor Research Group. Dr. Boockvar's laboratory interests have focused on studying adult human neural stem cell biology to investigate brain tumor formation and brain tumor and stem cell migration and survival. Dr. Boockvar's laboratory is funded by the National Cancer Institute. Dr. Boockvar served as Editor-in-Chief of the journal Current Stem Cell Research and Therapy and is an editorial board member of the journal Neurosurgery, and Recent Patents on Anti-Cancer Drug Discovery. He is an ad-hoc reviewer for Neurosurgery, Brain Research and Human Gene Therapy. Dr. Boockvar is a member of the Executive Committee of the Joint Section of Brain Tumors of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. He is the principal investigator of

new clinical trials using super selective intraarterial infusion techniques for the delivery of novel therapeutics such as Avastin or Cetuximab for the treatment of malignant brain cancer.

“We are excited to have Dr. Ram and Dr. Boockvar join our Scientific Advisory Board,” said Manish Singh, President and CEO of ImmunoCellular Therapeutics. “Both add invaluable expertise in the areas of neurosurgery and treatments of brain cancers, and we are confident their input will greatly enhance our research efforts and clinical activities.”

### **About ImmunoCellular Therapeutics, Ltd.**

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company’s “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company’s monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of \$32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com).

### **Forward-Looking Statements**

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that may be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner for ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC’s operations. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###